{
    "clinical_study": {
        "@rank": "57073", 
        "arm_group": {
            "arm_group_label": "WEB Aneurysm Embolization System", 
            "description": "Subjects aged \u2265 18 years, but \u2264 75 years requiring treatment for intracranial aneurysms."
        }, 
        "brief_summary": {
            "textblock": "An observational post-market, open label, multicenter Observatory. The decision to use a WEB\n      device to treat the patients has been made before and independently of the decision to\n      include the patient in the French Observatory."
        }, 
        "brief_title": "WEB French Observatory of the WEB Aneurysm Embolization System", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Brain Aneurysm", 
        "condition_browse": {
            "mesh_term": [
                "Aneurysm", 
                "Intracranial Aneurysm"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects will be screened for Observatory eligibility after giving informed consent.  The\n      embolization procedure will be performed in the digital angiographic suite using standard\n      angiographic techniques.\n\n      Initial analysis of Observatory data will be performed at completion of 12 month follow-up\n      for the first thirty-five (35) subjects.\n\n      Subjects will be followed per Institution's standard of care."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The decision to use a WEB device to treat the patients has been made before and\n             independently of the decision to include the patient in the French Observatory\n\n          2. Subject must be \u2265 18 years of age;\n\n          3. Subject must have an intracranial aneurysm requiring treatment according to a\n             multidisciplinary decision.  If the subject has an additional aneurysm requiring\n             treatment, the additional aneurysm must not require treatment within 30 days of the\n             index procedure;\n\n          4. Aneurysm to be treated must have the following characteristics:\n\n             i. Morphology - saccular ii. Location:\n\n               -  Basilar apex (BA), or\n\n               -  Middle cerebral artery (MCA) bifurcation,  or\n\n               -  Internal carotid artery (ICA) terminus\n\n               -  Anterior communicating artery (ACom)\n\n               -  Anterior cerebral Artery (ACA) iii. Diameter and width of the aneurysm is\n                  appropriate size for treatment with the WEB Aneurysm Embolization System per\n                  device Instructions for Use iv. Dome-to-Neck (DN) ratio  \u2265 1.0\n\n          5. Subject must be considered by the physician to be available for subsequent visits;\n\n          6. Subject must be able to comply with all aspects of the screening, evaluation,\n             treatment, and the post-procedure follow-up schedule;\n\n          7. Subject must sign and date CPP and/or CCTIRS/CNIL approved written informed consent\n             prior to initiation of any clinical evaluation procedures, including screening\n             procedures (if unable to sign for self, legal representative may do so where\n             applicable).\n\n        Additional inclusion criterion for ruptured aneurysms:\n\n        For subjects with ruptured aneurysm:  subject has ruptured aneurysm with Hunt & Hess Score\n        of I, II, or III\n\n        Exclusion Criteria:\n\n          -  1. Subject is greater than 75 years of age; 2. Subject has more than one aneurysm\n             requiring treatment within 30 days of index procedure; 3. Subject is female and\n             pregnant or breast-feeding; 4. Subject has a known coagulopathy; 5. Subject has a\n             known hemoglobinopathy or thrombocytopathy; 6. Subject has lesion with\n             characteristics unsuitable for endovascular treatment; 7. Subject has vessel,\n             tortuosity or morphology which could preclude safe access and support during\n             treatment with clinical evaluation device; 8. Subject exhibits ischemic symptoms such\n             as transient ischemic attacks, minor strokes, stroke-in-evolution within 30 days\n             prior to enrollment; 9. Subject exhibits clinical or angiographic evidence of\n             vasospasm; 10. Subject has physical, neurologic or psychiatric  conditions, which\n             preclude Subject's ability to comply with all aspects of the screening, evaluation,\n             treatment, and the post-procedure follow-up schedule; 11. Subject has known\n             hypersensitivity to any component of the clinical evaluation device, procedural\n             materials, or medications commonly used during the procedure; 12. Subject has\n             received any investigational device  for treatment of the target intracranial\n             aneurysm prior to entry into this trial; 13. Subject has an acute life-threatening\n             illness other than the neurological disease to be treated in this trial; 14. Subject\n             has a life expectancy of less than 2 years due to other illness or condition (in\n             addition to an intracranial aneurysm);\n\n        Additional Exclusion Criteria for unruptured aneurysms:\n\n        15. Subject has Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of\n        subarachnoid/intracranial hemorrhage on presentation; 16. Subject has any circulatory,\n        neurovascular, or cardiovascular medical conditions that have resulted in  neurological\n        symptoms;\n\n        Additional Exclusion Criteria for ruptured aneurysms:\n\n        17. Subject has a ruptured aneurysm and Hunt & Hess Score of IV or V;\n\n        Additional Imaging Exclusion Criteria:\n\n        18. Subject has CT or MRI evidence of intracranial tumor (except small meningioma) or any\n        other intracranial vascular malformations on presentation; 19. Subject has angiographic\n        evidence of vasculitis; 20. Microcatheter could not reach Subject's aneurysm to allow\n        necessary access to treat with clinical evaluation device"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The decision to use a WEB device to treat the patients has been made before and\n        independently of the decision to include the patient in the French Observatory"
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975233", 
            "org_study_id": "12001"
        }, 
        "intervention": {
            "arm_group_label": "WEB Aneurysm Embolization System", 
            "description": "WEB Aneurysm Embolization System", 
            "intervention_name": "WEB Aneurysm Embolization System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Endovascular", 
            "Brain Aneurysm"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "CHU Pellegrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14033"
                    }, 
                    "name": "CHU C\u00f4te de Nacre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France", 
                        "zip": "92110"
                    }, 
                    "name": "CHU Beaujon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69500"
                    }, 
                    "name": "H\u00f4pital Neurologique Pierre Wertheimer"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "H\u00f4pital Nord Laennec"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Potiers", 
                        "country": "France", 
                        "zip": "86021"
                    }, 
                    "name": "CHU La Miletrie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "51092"
                    }, 
                    "name": "CHU Reims - H\u00f4pital Maison-Blanche"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU Pontchailloux"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU Perpan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37000"
                    }, 
                    "name": "CHU Bretonneau"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "WEB French Observatory", 
        "other_outcome": [
            {
                "measure": "Modified Raymond Scale", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Percentage occlusion", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_official": {
            "affiliation": "CHU Reims", 
            "last_name": "Laurent Pierot, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
                "France: Conseil National de l'Ordre des M\u00e9decins"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The following efficacy assessments will be performed to assess the efficacy of the WEB Aneurysm Embolization System in the endovascular treatment of aneurysms.\n1. Durability of occlusion compared to post-procedure imaging\nDurability is defined as:\ni. No worsening of Raymond Class from post-procedure result to follow-up result and ii. Not classified as \"Recanalized\"", 
            "measure": "Durability of aneurysm occlusion", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Rate of aneurysm recanalization", 
            "measure": "Recurrence/recanalization rate", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Sequent Medical, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sequent Medical, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}